CN112656038A - 可重复密封的气溶胶生成制品 - Google Patents
可重复密封的气溶胶生成制品 Download PDFInfo
- Publication number
- CN112656038A CN112656038A CN202110052335.8A CN202110052335A CN112656038A CN 112656038 A CN112656038 A CN 112656038A CN 202110052335 A CN202110052335 A CN 202110052335A CN 112656038 A CN112656038 A CN 112656038A
- Authority
- CN
- China
- Prior art keywords
- aerosol
- source
- enhancing compound
- delivery enhancing
- volatile delivery
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims abstract description 136
- 230000002708 enhancing effect Effects 0.000 claims abstract description 112
- 239000003814 drug Substances 0.000 claims abstract description 88
- 238000004891 communication Methods 0.000 claims abstract description 10
- 239000012530 fluid Substances 0.000 claims abstract description 4
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims description 35
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims description 29
- 229960002715 nicotine Drugs 0.000 claims description 29
- 239000002253 acid Substances 0.000 claims description 5
- 238000001179 sorption measurement Methods 0.000 description 19
- -1 Polyethylene Polymers 0.000 description 16
- 239000000463 material Substances 0.000 description 16
- 238000011144 upstream manufacturing Methods 0.000 description 15
- 229910052751 metal Inorganic materials 0.000 description 12
- 239000002184 metal Substances 0.000 description 12
- 239000007788 liquid Substances 0.000 description 11
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 10
- 239000003463 adsorbent Substances 0.000 description 10
- 230000004888 barrier function Effects 0.000 description 8
- 239000000443 aerosol Substances 0.000 description 7
- PXHVJJICTQNCMI-UHFFFAOYSA-N nickel Substances [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 7
- 239000000919 ceramic Substances 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 229940107700 pyruvic acid Drugs 0.000 description 5
- FXFANIORDKRCCA-UHFFFAOYSA-N Norcotinine Chemical compound N1C(=O)CCC1C1=CC=CN=C1 FXFANIORDKRCCA-UHFFFAOYSA-N 0.000 description 4
- 229910045601 alloy Inorganic materials 0.000 description 4
- 239000000956 alloy Substances 0.000 description 4
- 239000003792 electrolyte Substances 0.000 description 4
- 239000011888 foil Substances 0.000 description 4
- ASUTZQLVASHGKV-JDFRZJQESA-N galanthamine Chemical compound O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 description 4
- 239000007789 gas Substances 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 150000002739 metals Chemical class 0.000 description 4
- DPNGWXJMIILTBS-UHFFFAOYSA-N myosmine Chemical compound C1CCN=C1C1=CC=CN=C1 DPNGWXJMIILTBS-UHFFFAOYSA-N 0.000 description 4
- 229910052759 nickel Inorganic materials 0.000 description 4
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- KWGRBVOPPLSCSI-WPRPVWTQSA-N L-Ephedrine Natural products CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 229910017052 cobalt Inorganic materials 0.000 description 3
- 239000010941 cobalt Substances 0.000 description 3
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 3
- 239000002131 composite material Substances 0.000 description 3
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 229910001220 stainless steel Inorganic materials 0.000 description 3
- 239000010935 stainless steel Substances 0.000 description 3
- 229910052719 titanium Inorganic materials 0.000 description 3
- 239000010936 titanium Substances 0.000 description 3
- CEMAWMOMDPGJMB-UHFFFAOYSA-N (+-)-Oxprenolol Chemical compound CC(C)NCC(O)COC1=CC=CC=C1OCC=C CEMAWMOMDPGJMB-UHFFFAOYSA-N 0.000 description 2
- XWTYSIMOBUGWOL-UHFFFAOYSA-N (+-)-Terbutaline Chemical compound CC(C)(C)NCC(O)C1=CC(O)=CC(O)=C1 XWTYSIMOBUGWOL-UHFFFAOYSA-N 0.000 description 2
- UIKROCXWUNQSPJ-VIFPVBQESA-N (-)-cotinine Chemical compound C1CC(=O)N(C)[C@@H]1C1=CC=CN=C1 UIKROCXWUNQSPJ-VIFPVBQESA-N 0.000 description 2
- RFEJUZJILGIRHQ-OMDKHLBYSA-N (2r,3r)-2,3-dihydroxybutanedioic acid;3-[(2s)-1-methylpyrrolidin-2-yl]pyridine Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.OC(=O)[C@H](O)[C@@H](O)C(O)=O.CN1CCC[C@H]1C1=CC=CN=C1 RFEJUZJILGIRHQ-OMDKHLBYSA-N 0.000 description 2
- UWYZHKAOTLEWKK-UHFFFAOYSA-N 1,2,3,4-tetrahydroisoquinoline Chemical compound C1=CC=C2CNCCC2=C1 UWYZHKAOTLEWKK-UHFFFAOYSA-N 0.000 description 2
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 2
- GPPUPQFYDYLTIY-UHFFFAOYSA-N 2-oxooctanoic acid Chemical compound CCCCCCC(=O)C(O)=O GPPUPQFYDYLTIY-UHFFFAOYSA-N 0.000 description 2
- KDVFRMMRZOCFLS-UHFFFAOYSA-N 2-oxopentanoic acid Chemical compound CCCC(=O)C(O)=O KDVFRMMRZOCFLS-UHFFFAOYSA-N 0.000 description 2
- QHKABHOOEWYVLI-UHFFFAOYSA-N 3-methyl-2-oxobutanoic acid Chemical compound CC(C)C(=O)C(O)=O QHKABHOOEWYVLI-UHFFFAOYSA-N 0.000 description 2
- BKAJNAXTPSGJCU-UHFFFAOYSA-N 4-methyl-2-oxopentanoic acid Chemical compound CC(C)CC(=O)C(O)=O BKAJNAXTPSGJCU-UHFFFAOYSA-N 0.000 description 2
- JOOXCMJARBKPKM-UHFFFAOYSA-N 4-oxopentanoic acid Chemical compound CC(=O)CCC(O)=O JOOXCMJARBKPKM-UHFFFAOYSA-N 0.000 description 2
- MXUNKHLAEDCYJL-UHFFFAOYSA-N 5-(hydroxymethyl)-3-(3-methylphenyl)-1,3-oxazolidin-2-one Chemical compound CC1=CC=CC(N2C(OC(CO)C2)=O)=C1 MXUNKHLAEDCYJL-UHFFFAOYSA-N 0.000 description 2
- UIKROCXWUNQSPJ-UHFFFAOYSA-N Cotinine Natural products C1CC(=O)N(C)C1C1=CC=CN=C1 UIKROCXWUNQSPJ-UHFFFAOYSA-N 0.000 description 2
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 2
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 2
- DMULVCHRPCFFGV-UHFFFAOYSA-N N,N-dimethyltryptamine Chemical compound C1=CC=C2C(CCN(C)C)=CNC2=C1 DMULVCHRPCFFGV-UHFFFAOYSA-N 0.000 description 2
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 2
- 241000208125 Nicotiana Species 0.000 description 2
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 2
- ILLGYRJAYAAAEW-QMMMGPOBSA-N abt-418 Chemical compound CN1CCC[C@H]1C1=CC(C)=NO1 ILLGYRJAYAAAEW-QMMMGPOBSA-N 0.000 description 2
- 150000004716 alpha keto acids Chemical class 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 2
- HJJPJSXJAXAIPN-UHFFFAOYSA-N arecoline Chemical compound COC(=O)C1=CCCN(C)C1 HJJPJSXJAXAIPN-UHFFFAOYSA-N 0.000 description 2
- QVQLCTNNEUAWMS-UHFFFAOYSA-N barium oxide Chemical compound [Ba]=O QVQLCTNNEUAWMS-UHFFFAOYSA-N 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- SOYKEARSMXGVTM-UHFFFAOYSA-N chlorphenamine Chemical compound C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 SOYKEARSMXGVTM-UHFFFAOYSA-N 0.000 description 2
- 229960003291 chlorphenamine Drugs 0.000 description 2
- 229960001747 cinchocaine Drugs 0.000 description 2
- PUFQVTATUTYEAL-UHFFFAOYSA-N cinchocaine Chemical compound C1=CC=CC2=NC(OCCCC)=CC(C(=O)NCCN(CC)CC)=C21 PUFQVTATUTYEAL-UHFFFAOYSA-N 0.000 description 2
- 229950006073 cotinine Drugs 0.000 description 2
- 229960002179 ephedrine Drugs 0.000 description 2
- 229920000295 expanded polytetrafluoroethylene Polymers 0.000 description 2
- 229960003980 galantamine Drugs 0.000 description 2
- ASUTZQLVASHGKV-UHFFFAOYSA-N galanthamine hydrochloride Natural products O1C(=C23)C(OC)=CC=C2CN(C)CCC23C1CC(O)C=C2 ASUTZQLVASHGKV-UHFFFAOYSA-N 0.000 description 2
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 238000005338 heat storage Methods 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- KUBCEEMXQZUPDQ-UHFFFAOYSA-N hordenine Chemical compound CN(C)CCC1=CC=C(O)C=C1 KUBCEEMXQZUPDQ-UHFFFAOYSA-N 0.000 description 2
- 239000011810 insulating material Substances 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 229960004194 lidocaine Drugs 0.000 description 2
- TYZROVQLWOKYKF-ZDUSSCGKSA-N linezolid Chemical compound O=C1O[C@@H](CNC(=O)C)CN1C(C=C1F)=CC=C1N1CCOCC1 TYZROVQLWOKYKF-ZDUSSCGKSA-N 0.000 description 2
- 229960003907 linezolid Drugs 0.000 description 2
- 229910052744 lithium Inorganic materials 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- IMYZQPCYWPFTAG-IQJOONFLSA-N mecamylamine Chemical compound C1C[C@@H]2C(C)(C)[C@@](NC)(C)[C@H]1C2 IMYZQPCYWPFTAG-IQJOONFLSA-N 0.000 description 2
- 229960002525 mecamylamine Drugs 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 229910001092 metal group alloy Inorganic materials 0.000 description 2
- 239000007769 metal material Substances 0.000 description 2
- LMOINURANNBYCM-UHFFFAOYSA-N metaproterenol Chemical compound CC(C)NCC(O)C1=CC(O)=CC(O)=C1 LMOINURANNBYCM-UHFFFAOYSA-N 0.000 description 2
- LBHIOVVIQHSOQN-UHFFFAOYSA-N nicorandil Chemical compound [O-][N+](=O)OCCNC(=O)C1=CC=CN=C1 LBHIOVVIQHSOQN-UHFFFAOYSA-N 0.000 description 2
- 229960002497 nicorandil Drugs 0.000 description 2
- 229960002657 orciprenaline Drugs 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 229960004570 oxprenolol Drugs 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 229920001707 polybutylene terephthalate Polymers 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 229920000139 polyethylene terephthalate Polymers 0.000 description 2
- 239000005020 polyethylene terephthalate Substances 0.000 description 2
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 2
- 239000004810 polytetrafluoroethylene Substances 0.000 description 2
- 229960003712 propranolol Drugs 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- IOVGROKTTNBUGK-SJCJKPOMSA-N ritodrine Chemical compound N([C@@H](C)[C@H](O)C=1C=CC(O)=CC=1)CCC1=CC=C(O)C=C1 IOVGROKTTNBUGK-SJCJKPOMSA-N 0.000 description 2
- 229960001634 ritodrine Drugs 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000002594 sorbent Substances 0.000 description 2
- 239000011232 storage material Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 229960001685 tacrine Drugs 0.000 description 2
- YLJREFDVOIBQDA-UHFFFAOYSA-N tacrine Chemical compound C1=CC=C2C(N)=C(CCCC3)C3=NC2=C1 YLJREFDVOIBQDA-UHFFFAOYSA-N 0.000 description 2
- GUVRBAGPIYLISA-UHFFFAOYSA-N tantalum atom Chemical compound [Ta] GUVRBAGPIYLISA-UHFFFAOYSA-N 0.000 description 2
- 229960000195 terbutaline Drugs 0.000 description 2
- 229960002309 toloxatone Drugs 0.000 description 2
- APJYDQYYACXCRM-UHFFFAOYSA-N tryptamine Chemical compound C1=CC=C2C(CCN)=CNC2=C1 APJYDQYYACXCRM-UHFFFAOYSA-N 0.000 description 2
- 229960001722 verapamil Drugs 0.000 description 2
- MXYUKLILVYORSK-UHFFFAOYSA-N (+/-)-allo-lobeline Natural products C1CCC(CC(=O)C=2C=CC=CC=2)N(C)C1CC(O)C1=CC=CC=C1 MXYUKLILVYORSK-UHFFFAOYSA-N 0.000 description 1
- ANJTVLIZGCUXLD-BDAKNGLRSA-N (-)-Cytisine Natural products C1NC[C@@H]2CN3C(=O)C=CC=C3[C@H]1C2 ANJTVLIZGCUXLD-BDAKNGLRSA-N 0.000 description 1
- MXYUKLILVYORSK-HBMCJLEFSA-N (-)-lobeline Chemical compound C1([C@@H](O)C[C@H]2N([C@H](CCC2)CC(=O)C=2C=CC=CC=2)C)=CC=CC=C1 MXYUKLILVYORSK-HBMCJLEFSA-N 0.000 description 1
- IGLYMJRIWWIQQE-QUOODJBBSA-N (1S,2R)-2-phenylcyclopropan-1-amine (1R,2S)-2-phenylcyclopropan-1-amine Chemical compound N[C@H]1C[C@@H]1C1=CC=CC=C1.N[C@@H]1C[C@H]1C1=CC=CC=C1 IGLYMJRIWWIQQE-QUOODJBBSA-N 0.000 description 1
- RILPIWOPNGRASR-UHFFFAOYSA-N (2R,3S)-2-Hydroxy-3-methylpentanoic acid Natural products CCC(C)C(O)C(O)=O RILPIWOPNGRASR-UHFFFAOYSA-N 0.000 description 1
- MTXSIJUGVMTTMU-JTQLQIEISA-N (S)-anabasine Chemical compound N1CCCC[C@H]1C1=CC=CN=C1 MTXSIJUGVMTTMU-JTQLQIEISA-N 0.000 description 1
- RKUNBYITZUJHSG-FXUDXRNXSA-N (S)-atropine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@H]3CC[C@@H](C2)N3C)=CC=CC=C1 RKUNBYITZUJHSG-FXUDXRNXSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- MYKUKUCHPMASKF-VIFPVBQESA-N (S)-nornicotine Chemical compound C1CCN[C@@H]1C1=CC=CN=C1 MYKUKUCHPMASKF-VIFPVBQESA-N 0.000 description 1
- OGNJZVNNKBZFRM-UHFFFAOYSA-N 1-(5-methoxy-1H-indol-3-yl)-2-propanamine Chemical compound COC1=CC=C2NC=C(CC(C)N)C2=C1 OGNJZVNNKBZFRM-UHFFFAOYSA-N 0.000 description 1
- VZLABKAAYLWGPQ-UHFFFAOYSA-N 2-(1h-indol-3-yl)-1-methoxy-n,n-dimethylethanamine Chemical compound C1=CC=C2C(CC(OC)N(C)C)=CNC2=C1 VZLABKAAYLWGPQ-UHFFFAOYSA-N 0.000 description 1
- SPCKHVPPRJWQRZ-UHFFFAOYSA-N 2-benzhydryloxy-n,n-dimethylethanamine;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 SPCKHVPPRJWQRZ-UHFFFAOYSA-N 0.000 description 1
- WGTASENVNYJZBK-UHFFFAOYSA-N 3,4,5-trimethoxyamphetamine Chemical compound COC1=CC(CC(C)N)=CC(OC)=C1OC WGTASENVNYJZBK-UHFFFAOYSA-N 0.000 description 1
- WAOQONBSWFLFPE-VIFPVBQESA-N 3,5-dichloro-N-[[(2S)-1-ethyl-2-pyrrolidinyl]methyl]-2-hydroxy-6-methoxybenzamide Chemical compound CCN1CCC[C@H]1CNC(=O)C1=C(O)C(Cl)=CC(Cl)=C1OC WAOQONBSWFLFPE-VIFPVBQESA-N 0.000 description 1
- MMOPGICOOYBFJU-UHFFFAOYSA-N 3-(1-methylpyrrolidin-2-yl)pyridine;2-oxopropanoic acid Chemical compound CC(=O)C(O)=O.CN1CCCC1C1=CC=CN=C1 MMOPGICOOYBFJU-UHFFFAOYSA-N 0.000 description 1
- HDJBTCAJIMNXEW-PPHPATTJSA-N 3-[(2s)-1-methylpyrrolidin-2-yl]pyridine;hydrochloride Chemical compound Cl.CN1CCC[C@H]1C1=CC=CN=C1 HDJBTCAJIMNXEW-PPHPATTJSA-N 0.000 description 1
- 239000001388 3-methyl-2-oxobutanoic acid Substances 0.000 description 1
- 239000001668 3-methyl-2-oxopentanoic acid Substances 0.000 description 1
- JVQYSWDUAOAHFM-UHFFFAOYSA-N 3-methyl-2-oxovaleric acid Chemical compound CCC(C)C(=O)C(O)=O JVQYSWDUAOAHFM-UHFFFAOYSA-N 0.000 description 1
- YSWVLPFCGJOQQA-UHFFFAOYSA-N 4-amino-5-chloro-n-[(1-ethylpyrrolidin-2-yl)methyl]-2-methoxybenzenesulfonamide Chemical compound CCN1CCCC1CNS(=O)(=O)C1=CC(Cl)=C(N)C=C1OC YSWVLPFCGJOQQA-UHFFFAOYSA-N 0.000 description 1
- 239000001142 4-methyl-2-oxopentanoic acid Substances 0.000 description 1
- XKFPYPQQHFEXRZ-UHFFFAOYSA-N 5-methyl-N'-(phenylmethyl)-3-isoxazolecarbohydrazide Chemical compound O1C(C)=CC(C(=O)NNCC=2C=CC=CC=2)=N1 XKFPYPQQHFEXRZ-UHFFFAOYSA-N 0.000 description 1
- 229930000680 A04AD01 - Scopolamine Natural products 0.000 description 1
- SOPPBXUYQGUQHE-UHFFFAOYSA-N Anatabine Natural products C1C=CCNC1C1=CC=CN=C1 SOPPBXUYQGUQHE-UHFFFAOYSA-N 0.000 description 1
- SOPPBXUYQGUQHE-JTQLQIEISA-N Anatabine Chemical compound C1C=CCN[C@@H]1C1=CC=CN=C1 SOPPBXUYQGUQHE-JTQLQIEISA-N 0.000 description 1
- 229930003347 Atropine Natural products 0.000 description 1
- 239000005528 B01AC05 - Ticlopidine Substances 0.000 description 1
- 206010073385 Blister rupture Diseases 0.000 description 1
- 229930008564 C01BA04 - Sparteine Natural products 0.000 description 1
- DBXFAPJCZABTDR-KUEXGRMWSA-N Cephalomannine Natural products O=C(O[C@@H]1C(C)=C2[C@@H](OC(=O)C)C(=O)[C@]3(C)[C@@H](O)C[C@@H]4[C@](OC(=O)C)([C@H]3[C@H](OC(=O)c3ccccc3)[C@@](O)(C2(C)C)C1)CO4)[C@@H](O)[C@H](NC(=O)/C(=C\C)/C)c1ccccc1 DBXFAPJCZABTDR-KUEXGRMWSA-N 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- NLPRAJRHRHZCQQ-UHFFFAOYSA-N Epibatidine Natural products C1=NC(Cl)=CC=C1C1C(N2)CCC2C1 NLPRAJRHRHZCQQ-UHFFFAOYSA-N 0.000 description 1
- 229910000640 Fe alloy Inorganic materials 0.000 description 1
- 229910000807 Ga alloy Inorganic materials 0.000 description 1
- GYHNNYVSQQEPJS-UHFFFAOYSA-N Gallium Chemical compound [Ga] GYHNNYVSQQEPJS-UHFFFAOYSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 1
- NYMGNSNKLVNMIA-UHFFFAOYSA-N Iproniazid Chemical compound CC(C)NNC(=O)C1=CC=NC=C1 NYMGNSNKLVNMIA-UHFFFAOYSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- JAQUASYNZVUNQP-USXIJHARSA-N Levorphanol Chemical compound C1C2=CC=C(O)C=C2[C@]23CCN(C)[C@H]1[C@@H]2CCCC3 JAQUASYNZVUNQP-USXIJHARSA-N 0.000 description 1
- 229910000914 Mn alloy Inorganic materials 0.000 description 1
- 229910001182 Mo alloy Inorganic materials 0.000 description 1
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 description 1
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 1
- 229910001257 Nb alloy Inorganic materials 0.000 description 1
- MYKUKUCHPMASKF-UHFFFAOYSA-N Nornicotine Natural products C1CCNC1C1=CC=CN=C1 MYKUKUCHPMASKF-UHFFFAOYSA-N 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- RMUCZJUITONUFY-UHFFFAOYSA-N Phenelzine Chemical compound NNCCC1=CC=CC=C1 RMUCZJUITONUFY-UHFFFAOYSA-N 0.000 description 1
- PIJVFDBKTWXHHD-UHFFFAOYSA-N Physostigmine Natural products C12=CC(OC(=O)NC)=CC=C2N(C)C2C1(C)CCN2C PIJVFDBKTWXHHD-UHFFFAOYSA-N 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- RVOLLAQWKVFTGE-UHFFFAOYSA-N Pyridostigmine Chemical compound CN(C)C(=O)OC1=CC=C[N+](C)=C1 RVOLLAQWKVFTGE-UHFFFAOYSA-N 0.000 description 1
- 229910052581 Si3N4 Inorganic materials 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 229910001128 Sn alloy Inorganic materials 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 229910001362 Ta alloys Inorganic materials 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- 229910001080 W alloy Inorganic materials 0.000 description 1
- QCWXUUIWCKQGHC-UHFFFAOYSA-N Zirconium Chemical compound [Zr] QCWXUUIWCKQGHC-UHFFFAOYSA-N 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 125000002015 acyclic group Chemical group 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 229910000272 alkali metal oxide Inorganic materials 0.000 description 1
- 229910001860 alkaline earth metal hydroxide Inorganic materials 0.000 description 1
- 229910000287 alkaline earth metal oxide Inorganic materials 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- SLRCCWJSBJZJBV-UHFFFAOYSA-N alpha-isosparteine Natural products C1N2CCCCC2C2CN3CCCCC3C1C2 SLRCCWJSBJZJBV-UHFFFAOYSA-N 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 229930014345 anabasine Natural products 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000004004 anti-anginal agent Substances 0.000 description 1
- 230000001088 anti-asthma Effects 0.000 description 1
- 239000003416 antiarrhythmic agent Substances 0.000 description 1
- 239000000924 antiasthmatic agent Substances 0.000 description 1
- 229940082992 antihypertensives mao inhibitors Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 239000007961 artificial flavoring substance Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 229960000396 atropine Drugs 0.000 description 1
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- YXTPWUNVHCYOSP-UHFFFAOYSA-N bis($l^{2}-silanylidene)molybdenum Chemical compound [Si]=[Mo]=[Si] YXTPWUNVHCYOSP-UHFFFAOYSA-N 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- SNPPWIUOZRMYNY-UHFFFAOYSA-N bupropion Chemical compound CC(C)(C)NC(C)C(=O)C1=CC=CC(Cl)=C1 SNPPWIUOZRMYNY-UHFFFAOYSA-N 0.000 description 1
- 229960001058 bupropion Drugs 0.000 description 1
- OJIJEKBXJYRIBZ-UHFFFAOYSA-N cadmium nickel Chemical compound [Ni].[Cd] OJIJEKBXJYRIBZ-UHFFFAOYSA-N 0.000 description 1
- 239000003990 capacitor Substances 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- DLNKOYKMWOXYQA-IONNQARKSA-N cathine Chemical compound C[C@H](N)[C@@H](O)C1=CC=CC=C1 DLNKOYKMWOXYQA-IONNQARKSA-N 0.000 description 1
- DBXFAPJCZABTDR-WBYYIXQISA-N cephalomannine Chemical compound O([C@@H]1[C@]2(O)C[C@@H](C(=C([C@@H](OC(C)=O)C(=O)[C@]3(C)[C@@H](O)C[C@H]4OC[C@]4([C@H]31)OC(C)=O)C2(C)C)C)OC(=O)[C@H](O)[C@@H](NC(=O)C(/C)=C/C)C=1C=CC=CC=1)C(=O)C1=CC=CC=C1 DBXFAPJCZABTDR-WBYYIXQISA-N 0.000 description 1
- 229910010293 ceramic material Inorganic materials 0.000 description 1
- 239000000544 cholinesterase inhibitor Substances 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- CKFRRHLHAJZIIN-UHFFFAOYSA-N cobalt lithium Chemical compound [Li].[Co] CKFRRHLHAJZIIN-UHFFFAOYSA-N 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 229930017327 cytisine Natural products 0.000 description 1
- ANJTVLIZGCUXLD-DTWKUNHWSA-N cytisine Chemical compound C1NC[C@H]2CN3C(=O)C=CC=C3[C@@H]1C2 ANJTVLIZGCUXLD-DTWKUNHWSA-N 0.000 description 1
- 229940027564 cytisine Drugs 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- KBEZZLAAKIIPFK-NJAFHUGGSA-N dimemorfan Chemical compound C1C2=CC=C(C)C=C2[C@@]23CCN(C)[C@@H]1[C@H]2CCCC3 KBEZZLAAKIIPFK-NJAFHUGGSA-N 0.000 description 1
- 229960001056 dimemorfan Drugs 0.000 description 1
- 229960000520 diphenhydramine Drugs 0.000 description 1
- DLNKOYKMWOXYQA-UHFFFAOYSA-N dl-pseudophenylpropanolamine Natural products CC(N)C(O)C1=CC=CC=C1 DLNKOYKMWOXYQA-UHFFFAOYSA-N 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000013013 elastic material Substances 0.000 description 1
- 238000004146 energy storage Methods 0.000 description 1
- ANJTVLIZGCUXLD-UHFFFAOYSA-N ent-cytisine Natural products C1NCC2CN3C(=O)C=CC=C3C1C2 ANJTVLIZGCUXLD-UHFFFAOYSA-N 0.000 description 1
- NLPRAJRHRHZCQQ-IVZWLZJFSA-N epibatidine Chemical compound C1=NC(Cl)=CC=C1[C@@H]1[C@H](N2)CC[C@H]2C1 NLPRAJRHRHZCQQ-IVZWLZJFSA-N 0.000 description 1
- 230000005496 eutectics Effects 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 229940074391 gallic acid Drugs 0.000 description 1
- 235000004515 gallic acid Nutrition 0.000 description 1
- 239000003365 glass fiber Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 239000010439 graphite Substances 0.000 description 1
- 229910002804 graphite Inorganic materials 0.000 description 1
- 229910052735 hafnium Inorganic materials 0.000 description 1
- VBJZVLUMGGDVMO-UHFFFAOYSA-N hafnium atom Chemical compound [Hf] VBJZVLUMGGDVMO-UHFFFAOYSA-N 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 229940071490 hordenine Drugs 0.000 description 1
- 229930005342 hyoscyamine Natural products 0.000 description 1
- 229960003210 hyoscyamine Drugs 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 229940070023 iproniazide Drugs 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 229960002672 isocarboxazid Drugs 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000011133 lead Substances 0.000 description 1
- 229960003406 levorphanol Drugs 0.000 description 1
- 229940040102 levulinic acid Drugs 0.000 description 1
- GELKBWJHTRAYNV-UHFFFAOYSA-K lithium iron phosphate Chemical compound [Li+].[Fe+2].[O-]P([O-])([O-])=O GELKBWJHTRAYNV-UHFFFAOYSA-K 0.000 description 1
- FUJCRWPEOMXPAD-UHFFFAOYSA-N lithium oxide Chemical compound [Li+].[Li+].[O-2] FUJCRWPEOMXPAD-UHFFFAOYSA-N 0.000 description 1
- 229910001947 lithium oxide Inorganic materials 0.000 description 1
- 229960002339 lobeline Drugs 0.000 description 1
- 229930013610 lobeline Natural products 0.000 description 1
- 229950001301 lorapride Drugs 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 229960000582 mepyramine Drugs 0.000 description 1
- YECBIJXISLIIDS-UHFFFAOYSA-N mepyramine Chemical compound C1=CC(OC)=CC=C1CN(CCN(C)C)C1=CC=CC=N1 YECBIJXISLIIDS-UHFFFAOYSA-N 0.000 description 1
- 229910052987 metal hydride Inorganic materials 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- SVXZBICQLNEMLC-UHFFFAOYSA-N methyl 1-methyl-3,6-dihydro-2h-pyridine-4-carboxylate Chemical compound COC(=O)C1=CCN(C)CC1 SVXZBICQLNEMLC-UHFFFAOYSA-N 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 229960004644 moclobemide Drugs 0.000 description 1
- YHXISWVBGDMDLQ-UHFFFAOYSA-N moclobemide Chemical compound C1=CC(Cl)=CC=C1C(=O)NCCN1CCOCC1 YHXISWVBGDMDLQ-UHFFFAOYSA-N 0.000 description 1
- 239000011733 molybdenum Substances 0.000 description 1
- 229910021343 molybdenum disilicide Inorganic materials 0.000 description 1
- 239000002899 monoamine oxidase inhibitor Substances 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 229910000623 nickel–chromium alloy Inorganic materials 0.000 description 1
- 229940069688 nicotine bitartrate Drugs 0.000 description 1
- 239000010955 niobium Substances 0.000 description 1
- GUCVJGMIXFAOAE-UHFFFAOYSA-N niobium atom Chemical compound [Nb] GUCVJGMIXFAOAE-UHFFFAOYSA-N 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 235000019809 paraffin wax Nutrition 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 229960000964 phenelzine Drugs 0.000 description 1
- PIJVFDBKTWXHHD-HIFRSBDPSA-N physostigmine Chemical compound C12=CC(OC(=O)NC)=CC=C2N(C)[C@@H]2[C@@]1(C)CCN2C PIJVFDBKTWXHHD-HIFRSBDPSA-N 0.000 description 1
- 229960001697 physostigmine Drugs 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920005594 polymer fiber Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 239000005373 porous glass Substances 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- KWGRBVOPPLSCSI-WCBMZHEXSA-N pseudoephedrine Chemical compound CN[C@@H](C)[C@@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WCBMZHEXSA-N 0.000 description 1
- 229960003908 pseudoephedrine Drugs 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 229960002290 pyridostigmine Drugs 0.000 description 1
- 229950001518 raclopride Drugs 0.000 description 1
- 239000012858 resilient material Substances 0.000 description 1
- YJYPZLAZNIGNRP-UHFFFAOYSA-N rjr-2429 Chemical compound C1CN2CCC1CC2C1=CC=CN=C1 YJYPZLAZNIGNRP-UHFFFAOYSA-N 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 1
- 229960002646 scopolamine Drugs 0.000 description 1
- 239000004065 semiconductor Substances 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- HBMJWWWQQXIZIP-UHFFFAOYSA-N silicon carbide Chemical compound [Si+]#[C-] HBMJWWWQQXIZIP-UHFFFAOYSA-N 0.000 description 1
- 229910010271 silicon carbide Inorganic materials 0.000 description 1
- HQVNEWCFYHHQES-UHFFFAOYSA-N silicon nitride Chemical compound N12[Si]34N5[Si]62N3[Si]51N64 HQVNEWCFYHHQES-UHFFFAOYSA-N 0.000 description 1
- 229920002379 silicone rubber Polymers 0.000 description 1
- 239000004945 silicone rubber Substances 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 239000000779 smoke Substances 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000017550 sodium carbonate Nutrition 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000011083 sodium citrates Nutrition 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- SLRCCWJSBJZJBV-AJNGGQMLSA-N sparteine Chemical compound C1N2CCCC[C@H]2[C@@H]2CN3CCCC[C@H]3[C@H]1C2 SLRCCWJSBJZJBV-AJNGGQMLSA-N 0.000 description 1
- 229960001945 sparteine Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229910052715 tantalum Inorganic materials 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- PHWBOXQYWZNQIN-UHFFFAOYSA-N ticlopidine Chemical compound ClC1=CC=CC=C1CN1CC(C=CS2)=C2CC1 PHWBOXQYWZNQIN-UHFFFAOYSA-N 0.000 description 1
- 229960005001 ticlopidine Drugs 0.000 description 1
- 229960003741 tranylcypromine Drugs 0.000 description 1
- WFKWXMTUELFFGS-UHFFFAOYSA-N tungsten Chemical compound [W] WFKWXMTUELFFGS-UHFFFAOYSA-N 0.000 description 1
- 239000010937 tungsten Substances 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 229910052726 zirconium Inorganic materials 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
- A24F—SMOKERS' REQUISITES; MATCH BOXES; SIMULATED SMOKING DEVICES
- A24F40/00—Electrically operated smoking devices; Component parts thereof; Manufacture thereof; Maintenance or testing thereof; Charging means specially adapted therefor
- A24F40/40—Constructional details, e.g. connection of cartridges and battery parts
-
- A—HUMAN NECESSITIES
- A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
- A24F—SMOKERS' REQUISITES; MATCH BOXES; SIMULATED SMOKING DEVICES
- A24F40/00—Electrically operated smoking devices; Component parts thereof; Manufacture thereof; Maintenance or testing thereof; Charging means specially adapted therefor
- A24F40/30—Devices using two or more structurally separated inhalable precursors, e.g. using two liquid precursors in two cartridges
-
- A—HUMAN NECESSITIES
- A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
- A24B—MANUFACTURE OR PREPARATION OF TOBACCO FOR SMOKING OR CHEWING; TOBACCO; SNUFF
- A24B15/00—Chemical features or treatment of tobacco; Tobacco substitutes, e.g. in liquid form
- A24B15/10—Chemical features of tobacco products or tobacco substitutes
- A24B15/16—Chemical features of tobacco products or tobacco substitutes of tobacco substitutes
- A24B15/167—Chemical features of tobacco products or tobacco substitutes of tobacco substitutes in liquid or vaporisable form, e.g. liquid compositions for electronic cigarettes
-
- A—HUMAN NECESSITIES
- A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
- A24F—SMOKERS' REQUISITES; MATCH BOXES; SIMULATED SMOKING DEVICES
- A24F40/00—Electrically operated smoking devices; Component parts thereof; Manufacture thereof; Maintenance or testing thereof; Charging means specially adapted therefor
- A24F40/40—Constructional details, e.g. connection of cartridges and battery parts
- A24F40/42—Cartridges or containers for inhalable precursors
-
- A—HUMAN NECESSITIES
- A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
- A24F—SMOKERS' REQUISITES; MATCH BOXES; SIMULATED SMOKING DEVICES
- A24F40/00—Electrically operated smoking devices; Component parts thereof; Manufacture thereof; Maintenance or testing thereof; Charging means specially adapted therefor
- A24F40/40—Constructional details, e.g. connection of cartridges and battery parts
- A24F40/48—Fluid transfer means, e.g. pumps
- A24F40/485—Valves; Apertures
-
- A—HUMAN NECESSITIES
- A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
- A24F—SMOKERS' REQUISITES; MATCH BOXES; SIMULATED SMOKING DEVICES
- A24F47/00—Smokers' requisites not otherwise provided for
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
- A61M11/04—Sprayers or atomisers specially adapted for therapeutic purposes operated by the vapour pressure of the liquid to be sprayed or atomised
- A61M11/041—Sprayers or atomisers specially adapted for therapeutic purposes operated by the vapour pressure of the liquid to be sprayed or atomised using heaters
- A61M11/042—Sprayers or atomisers specially adapted for therapeutic purposes operated by the vapour pressure of the liquid to be sprayed or atomised using heaters electrical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0001—Details of inhalators; Constructional features thereof
- A61M15/0003—Details of inhalators; Constructional features thereof with means for dispensing more than one drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0001—Details of inhalators; Constructional features thereof
- A61M15/0021—Mouthpieces therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0065—Inhalators with dosage or measuring devices
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/06—Inhaling appliances shaped like cigars, cigarettes or pipes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
- A61M16/20—Valves specially adapted to medical respiratory devices
- A61M16/201—Controlled valves
-
- A—HUMAN NECESSITIES
- A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
- A24F—SMOKERS' REQUISITES; MATCH BOXES; SIMULATED SMOKING DEVICES
- A24F40/00—Electrically operated smoking devices; Component parts thereof; Manufacture thereof; Maintenance or testing thereof; Charging means specially adapted therefor
- A24F40/10—Devices using liquid inhalable precursors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
- A61M11/04—Sprayers or atomisers specially adapted for therapeutic purposes operated by the vapour pressure of the liquid to be sprayed or atomised
- A61M11/041—Sprayers or atomisers specially adapted for therapeutic purposes operated by the vapour pressure of the liquid to be sprayed or atomised using heaters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0001—Details of inhalators; Constructional features thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0001—Details of inhalators; Constructional features thereof
- A61M15/0021—Mouthpieces therefor
- A61M15/0023—Mouthpieces therefor retractable
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
- A61M15/003—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using capsules, e.g. to be perforated or broken-up
- A61M15/0031—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using capsules, e.g. to be perforated or broken-up by bursting or breaking the package, i.e. without cutting or piercing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
- A61M15/003—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using capsules, e.g. to be perforated or broken-up
- A61M15/0043—Non-destructive separation of the package, e.g. peeling
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
- A61M15/0045—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using multiple prepacked dosages on a same carrier, e.g. blisters
- A61M15/0046—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using multiple prepacked dosages on a same carrier, e.g. blisters characterized by the type of carrier
- A61M15/0048—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using multiple prepacked dosages on a same carrier, e.g. blisters characterized by the type of carrier the dosages being arranged in a plane, e.g. on diskettes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
- A61M15/0045—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using multiple prepacked dosages on a same carrier, e.g. blisters
- A61M15/0046—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using multiple prepacked dosages on a same carrier, e.g. blisters characterized by the type of carrier
- A61M15/005—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using multiple prepacked dosages on a same carrier, e.g. blisters characterized by the type of carrier the dosages being arranged on a cylindrical surface
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/04—Liquids
- A61M2202/0468—Liquids non-physiological
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/33—Controlling, regulating or measuring
- A61M2205/3368—Temperature
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/36—General characteristics of the apparatus related to heating or cooling
- A61M2205/364—General characteristics of the apparatus related to heating or cooling by chemical reaction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/36—General characteristics of the apparatus related to heating or cooling
- A61M2205/3646—General characteristics of the apparatus related to heating or cooling by heat accumulators, e.g. ice, sand
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/36—General characteristics of the apparatus related to heating or cooling
- A61M2205/3653—General characteristics of the apparatus related to heating or cooling by Joule effect, i.e. electric resistance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/50—General characteristics of the apparatus with microprocessors or computers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/82—Internal energy supply devices
- A61M2205/8206—Internal energy supply devices battery-operated
Abstract
提供一种气溶胶形成制品(12),所述气溶胶形成制品(12)包括气流入口(37)和气流出口(34)。所述气溶胶形成制品(12)进一步包括位于所述气流入口(37)与所述气流出口(34)之间的药剂源(22)和挥发性递送增强化合物源(24),以及可移动部分(32)。所述可移动部分(32)可在打开位置与关闭位置之间移动,在所述打开位置处,所述药剂源(22)和所述挥发性递送增强化合物源(24)与所述气流入口(37)和所述气流出口(34)两者流体连通,在所述关闭位置处,所述药剂源(22)和所述挥发性递送增强化合物源(24)中的每一个与所述气流入口(37)和所述气流出口(34)中的仅一个连通或不与其连通。
Description
本申请是申请日为2016年3月24日、国际申请号为PCT/EP2016/056578、国家申请号为201680015125.9、发明名称为“可重复密封的气溶胶生成制品”的中国发明专利申请的分案申请。
技术领域
本发明涉及一种气溶胶生成系统,其用于生成包括药剂的气溶胶。本发明发现作为用于生成包括尼古丁盐颗粒的气溶胶的气溶胶生成系统的特定应用。
背景技术
用于向用户递送尼古丁或其它药剂的一些装置包括挥发性酸(如丙酮酸)或其它挥发性递送增强化合物源和尼古丁或其它药剂源。挥发性递送增强化合物与尼古丁在气相中反应形成尼古丁盐颗粒的气溶胶,所述气溶胶会被用户吸入。
在室温下,丙酮酸和尼古丁均是充分挥发的以形成相应的蒸汽,所述蒸汽在气相中彼此反应以形成尼古丁丙酮酸盐颗粒。因此,为防止挥发性递送增强化合物和尼古丁的过早蒸发,通常会用一个或多个易破密封件密封两种源,用户必须破坏所述密封件才能使用气溶胶生成系统。然而,在一个或多个易破密封件被破坏后,用户在挥发性递送增强化合物和尼古丁从系统中蒸发之前通常仅具有有限时间来使用气溶胶生成系统。
在包括尼古丁或其它药剂源和挥发性递送增强化合物源的装置中,将期望允许消费者在延长的时间段内使用所述装置,同时将药剂和挥发性递送增强化合物源的蒸发逸出量降到最低。
发明内容
本发明提供一种气溶胶形成制品,所述气溶胶形成制品包括气流入口和气流出口。气溶胶形成制品进一步包括位于气流入口与气流出口之间的药剂源和挥发性递送增强化合物源,以及可移动部分。所述可移动部分可在打开位置与关闭位置之间移动,在打开位置处,药剂源和挥发性递送增强化合物源与气流入口和气流出口两者流体连通,在关闭位置处,药剂源和挥发性递送增强化合物源中的每一个与气流入口和气流出口中的仅一个连通或不与其连通。
如本文所使用,术语“气溶胶生成装置”是指与气溶胶生成制品相互作用以生成气溶胶的装置,所述气溶胶可通过用户的口腔被直接吸入用户的肺内。
如本文所使用,术语“气溶胶生成制品”是指包括可形成气溶胶的能够释放挥发性化合物的气溶胶形成基质的制品。气溶胶生成制品可包括可形成气溶胶的能够在加热后释放挥发性化合物的气溶胶形成基质。气溶胶生成制品可完全为可消耗的并且主要包括药剂源和挥发性递送增强化合物。气溶胶生成制品可包括被配置成附接于气溶胶生成装置的可再用部分(如烟嘴)和包括药剂和挥发性递送增强化合物源并且被配置成插入于可再用部分中的可消耗部分。
如本文中所使用,术语“气溶胶生成系统”是指气溶胶生成制品与气溶胶生成装置的组合。
如本文中所使用,术语“药剂源”是指预期用于向用户的肺部递送的一种或多种挥发性化合物的来源。在优选实施例中,药剂源包括尼古丁源。
如本文中所使用,术语“挥发性递送增强化合物源”是指一种或多种挥发性化合物的来源,所述一种或多种挥发性化合物与药剂源在气相中反应以帮助从药剂源向用户递送一种或多种化合物。
通过提供可防止药剂和挥发性递送增强化合物源中的每一个与气流入口和气流出口中的一个或两个之间发生流体连通的可移动部分,根据本发明的气溶胶生成制品可减少或消除药剂和挥发性递送增强化合物变坏和蒸发逸出。因此,在首次使用制品之后,用户不需要直接消耗掉全部药剂和挥发性递送增强化合物。取而代之,用户可消耗一部分药剂和挥发性递送增强化合物并随后关闭气溶胶生成制品的可移动部分,直到随后用户希望进一步使用所述制品的某个时间为止。
气溶胶形成制品可进一步包括内部部分,在所述内部部分上提供药剂源和挥发性递送增强化合物源,其中可移动部分包括含有所述内部部分的外部壳体,所述外部壳体被配置成相对于内部部分相对移动。外部壳体可为管状外部壳体并且内部部分可为含于外部壳体中的管状或圆柱状内部部分。外部壳体可被配置成相对于内部部分相对旋转移动。
在包括可相对于内部部分移动的外部壳体的那些实施例中,气溶胶形成制品可包括至少一个密封件。至少一个密封件可包括固定到外部壳体的内表面的第一端部和固定到内部部分的第二端部。外部壳体的内表面可与内部部分间隔开,并且外部壳体可在关闭位置与打开位置之间移动,在所述关闭位置处,至少一个密封件覆盖药剂源和挥发性递送增强化合物源,在所述打开位置处,药剂源和挥发性递送增强化合物源至少部分未被覆盖。
在其中内部部分为管状或圆柱状内部部分的那些实施例中,其可进一步包括其中提供有药剂源的第一凹部和其中提供有挥发性递送增强化合物源的第二凹部。至少一个密封件可包括片材的至少一部分,其包括固定到外部壳体的内表面的第一端部和固定到邻近于凹部的内部部分的第二端部。
在其中外部壳体为可相对于管状或圆柱状内部部分沿圆周方向旋转的管状外部壳体的那些实施例中,当外部壳体处于关闭位置时,片材的第一端部可位于邻近于凹部的第一侧的内部部分之上,并且片材的第二端部可固定到邻近于凹部的第二侧的内部部分,其中第一和第二侧沿圆周方向与其间的凹部间隔开。当外部壳体沿圆周方向旋转到打开位置处时,片材的第一端部位于邻近于凹部的第二侧的内部部分之上以使得凹部不再被片材覆盖。
片材优选为非可渗透的无弹性材料,如金属箔或基本无弹性的塑料。片材的至少一部分可包括用于密封含有药剂源的凹部的第一片材部分和用于密封含有挥发性递送增强化合物源的凹部的第二片材部分。片材的至少一部分可包括可重复密封的胶粘剂,其提供于当外部壳体处于关闭位置时接触内部部分的片材表面上。
作为使用片材的一个或多个部分形成密封件的替代方案,外部壳体可改为被配置成使得其可在关闭位置与打开位置之间移动,在所述关闭位置处,外部壳体的内表面接触内部部分并且覆盖药剂源和挥发性递送增强化合物源,在所述打开位置处,外部壳体的内表面与内部部分间隔开以使得药剂源和挥发性递送增强化合物源未被覆盖。外部壳体的内表面可包括锥形部分。
外部壳体可为管状外部壳体并且内部部分可为管状或圆柱状内部部分,其中外部壳体可相对于内部部分沿圆周方向旋转。内部部分优选包括其中提供有药剂源的第一凹部和其中提供有挥发性递送增强化合物源的第二凹部。当外部壳体处于关闭位置而使得每一凹部被密封时,外部壳体的内表面可接触环绕每一凹部的周界的内部部分。
在其中外部壳体可相对于内部部分沿圆周方向旋转的那些实施例中,外部壳体可包括具有偏离于外部壳体的旋转中心的中心的圆形横截面形状。在这种情况下,当外部壳体从打开位置移动到关闭位置时,外部壳体的偏心旋转提供外部壳体与内部部分之间的接触。外部壳体或内部部分可具有非圆形横截面形状,如椭圆形或卵形以实现相同作用。
作为提供可相对于如上文所述的内部部分移动的外部壳体的替代方案,根据本发明的气溶胶形成制品可改为包括其中提供有气流入口和气流出口的外部壳体,和含于外部壳体中并且在气流入口与气流出口之间延伸的气流通道。药剂源和挥发性递送增强化合物源可提供在气流通道中,并且可移动部分可在关闭位置与打开位置之间移动,在所述关闭位置处,可移动部分阻碍气流通道以防止气流入口与气流出口之间的气流通过气流通道,在所述打开位置处,气流通道不受阻碍。
优选的是,可移动部分包括第一端部和第二端部,所述第一端部被配置成当可移动部分处于关闭位置时,阻碍气流通道,所述第二端部延伸通过外部壳体中的开孔,以允许用户使用可移动部分的第二端部以在打开位置与关闭位置之间移动可移动部分。可移动部分可包括延伸通过外部壳体中的开孔的按钮。按钮优选包含将按钮选择性地保持在打开和关闭位置中的一个或两个处的锁定机构。按钮可包括偏置构件,如弹簧以朝向打开位置偏置按钮,和将按钮选择性地保持在关闭位置处的锁定机构。
在上述实施例中的任一个中,气溶胶生成制品可进一步包括一个或多个易破阻挡层,其为药剂源和挥发性递送增强化合物源中的一个或两个提供初始密封件。通过易破阻挡层提供的密封件可不同于通过可移动部分提供的重新密封作用。在可使用气溶胶生成制品之前,可能需要不可逆地刺穿易破阻挡层或者使易破阻挡层破裂。药剂和挥发性递送增强化合物中的至少一种可为密封于形成易破阻挡层的泡壳中的液体。在包括一个或多个易破阻挡层的那些实施例中,气溶胶生成制品可包含至少一个刺穿元件或破裂部分以破坏易破阻挡层。或者,至少一个刺穿元件或破裂部分可形成与气溶胶生成制品一起使用的气溶胶生成装置的一部分。
在这点上,本发明扩展到一种气溶胶生成系统,其包括根据上述实施例中的任一个的气溶胶生成制品和气溶胶生成装置,所述气溶胶生成装置包括加热器元件。
在上述实施例中的任一个中,药剂源和挥发性递送增强化合物源优选串联布置在气溶胶生成制品中。
如本文中所使用,“串联”意指药剂源和挥发性递送增强化合物源被布置在气溶胶生成制品中以使得在使用时,抽吸通过气溶胶生成制品的空气流经过药剂源和挥发性递送增强化合物源中的一种,并且随后经过药剂源和挥发性递送增强化合物源中的另一种。优选的是,药剂源在挥发性递送增强化合物源的上游以使得在使用时药剂蒸汽从药剂源释放到抽吸通过气溶胶生成制品的空气流中,并且挥发性递送增强化合物蒸汽从挥发性递送增强化合物源释放到抽吸通过气溶胶生成制品的含药剂的空气流中。药剂蒸汽与挥发性递送增强化合物蒸汽在气相中反应形成气溶胶,所述气溶胶被递送给用户。
药剂源和挥发性递送增强化合物源可平行布置在气溶胶生成制品中。
挥发性递送增强化合物的蒸汽压优选为至少约20Pa、更优选为至少约50Pa、更优选为至少约75Pa、最优选为至少100Pa。除非另有说明,否则本文中提及的所有蒸汽压均是在25℃下根据ASTM E1194-07测量。
挥发性递送增强化合物在25℃下的蒸汽压优选小于或等于约400Pa、更优选小于或等于约300Pa、甚至更优选小于或等于约275Pa、最优选小于或等于约250Pa。
挥发性递送增强化合物在25℃下的蒸汽压可在约20Pa与约400Pa之间、更优选约20Pa与约300Pa之间、甚至更优选约20Pa与约275Pa之间、最优选约20Pa与约250Pa之间。
挥发性递送增强化合物在25℃下的蒸汽压可在约50Pa与约400Pa之间、更优选约50Pa与约300Pa之间、甚至更优选约50Pa与约275Pa之间、最优选约50Pa与约250Pa之间。
挥发性递送增强化合物在25℃下的蒸汽压可在约75Pa与约400Pa之间、更优选约75Pa与约300Pa之间、甚至更优选约75Pa与约275Pa之间、最优选约75Pa与约250Pa之间。
挥发性递送增强化合物在25℃下的蒸汽压可在约100Pa与约400Pa之间、更优选约100Pa与约300Pa之间、甚至更优选约100Pa与约275Pa之间、最优选约100Pa与约250Pa之间。
挥发性递送增强化合物可包括单一化合物。挥发性递送增强化合物可包括两种或更多种不同化合物。
在挥发性递送增强化合物包括两种或更多种不同化合物的情况下,呈组合形式的两种或更多种不同化合物在25℃下的蒸汽压为至少约20Pa。
优选的是,挥发性递送增强化合物是挥发性液体。
挥发性递送增强化合物可包括两种或更多种不同液体化合物的混合物。
挥发性递送增强化合物可包括一种或多种化合物的水溶液。挥发性递送增强化合物可包括一种或多种化合物的非水溶液。
挥发性递送增强化合物可包括两种或更多种不同挥发性化合物。挥发性递送增强化合物可包括两种或更多种不同挥发性液体化合物的混合物。
挥发性递送增强化合物可包括一种或多种非挥发性化合物和一种或多种挥发性化合物。挥发性递送增强化合物可包括一种或多种非挥发性化合物于挥发性溶剂中的溶液或一种或多种非挥发性液体化合物与一种或多种挥发性液体化合物的混合物。
挥发性递送增强化合物包括酸。挥发性递送增强化合物可包括有机酸或无机酸。优选的是,挥发性递送增强化合物包括有机酸,更优选羧酸,最优选α-酮酸或2-氧代酸。挥发性递送增强化合物可包括乳酸。其它合适酸包含天冬氨酸、谷氨酸、水杨酸、酒石酸、没食子酸、乙酰丙酸、乙酸、苹果酸、柠檬酸、草酸、硫酸、棕榈酸和海藻酸。
优选的是,挥发性递送增强化合物包括选自由3-甲基-2-氧代戊酸、丙酮酸、2-氧代戊酸、4-甲基-2-氧代戊酸、3-甲基-2-氧代丁酸、2-氧代辛酸以及其组合组成的群组的酸。在一个特别优选的实施例中,挥发性递送增强化合物包括丙酮酸。
挥发性递送增强化合物源包括吸附元件和被吸附在所述吸附元件上的挥发性递送增强化合物。在制造期间挥发性递送增强化合物可吸附在吸附元件上并且可对吸附元件加以密封。挥发性递送增强化合物可与吸附元件分开储存,例如储存在吸附元件上或邻近吸附元件的泡壳中。当挥发性递送增强化合物被释放并被吸附在吸附元件上时,可形成挥发性递送增强化合物源。
如本文所使用,“吸附”意指挥发性递送增强化合物被吸收在吸附元件的表面上,或被吸收在吸附元件中,或被吸收在吸附元件上并且被吸收在吸附元件中。优选的是,挥发性递送增强化合物被吸收在吸附元件上。
吸附元件可由任何合适的材料或材料组合来形成。吸附元件可包括玻璃、不锈钢、铝、聚乙烯(PE)、聚丙烯、聚对苯二甲酸乙二酯(PET)、聚对苯二甲酸丁二酯(PBT)、聚四氟乙烯(PTFE)、膨胀性聚四氟乙烯(ePTFE)和中的一种或多种。
在一个优选的实施例中,吸附元件为多孔吸附元件。
吸附元件可为多孔吸附元件,其包括选自由多孔塑料材料、多孔聚合物纤维和多孔玻璃纤维组成的群组的一种或多种材料。
就挥发性递送增强化合物来说,吸附元件优选是化学惰性的。
吸附元件可具有任何合适的大小和形状。
可对吸附元件的大小、形状和组成加以选择为允许所需量的挥发性递送增强化合物被吸附到吸附元件上。
优选的是,使约20μl与约200μl之间、更优选约40μl与约150μl之间、最优选约50μl与约100μl之间的挥发性递送增强化合物被吸附在吸附元件上。
吸附元件宜充当挥发性递送增强化合物的储存器。
优选的是,药剂的熔点低于约150摄氏度。
替代地或另外,优选的是,药剂的沸点低于约300摄氏度。
优选的是,药剂包括一种或多种脂族或芳香族、饱和或不饱和含氮碱(含氮的碱性化合物),其中氮原子存在于杂环中或非环链中(取代)。
药剂可包括选自由以下组成的群组的一种或多种化合物:尼古丁;7-羟基帽柱木碱(7-Hydroxymitragynine);槟榔碱;阿托品;安非他酮;去甲麻黄碱(D-去甲伪麻黄碱);氯苯那敏(Chlorpheneramine);地布卡因(Dibucaine);二甲啡烷,二甲基色胺,苯海拉明,麻黄碱,大麦芽碱,莨菪碱,异槟榔碱,左啡诺,山梗菜碱,松叶菊碱,帽柱木碱,马斯卡廷(Muscatine),普鲁卡因,伪麻黄碱,吡拉明,雷氯必利(Raclopride),利托君(Ritodrine),东莨菪碱,金雀花碱(鹰爪豆碱)和噻氯匹啶;烟草烟气成分,如1,2,3,4四氢异喹啉、假木贼碱(Anabasine)、新烟草碱、可替宁(Cotinine)、麦斯明(Myosmine)、尼古崔(Nicotrine)、降可替宁(Norcotinine)和降尼古丁;抗哮喘药,如奥西那林(Orciprenaline)、普萘洛尔(Propranolol)和特布他林(Terbutaline);抗心绞痛药,如尼可地尔(Nicorandil)、氧烯洛尔(Oxprenolol)和维拉帕米(Verapamil);抗心律失常药,如利多卡因(Lidocaine);尼古丁激动剂,如地棘蛙素(Epibatidine)、5-(2R)-吖丁啶基甲氧基)-2-氯吡啶(ABT-594)、(S)-3-甲基-5-(l-甲基-2-吡咯烷基)异恶唑(ABT 418)和(±)-2-(3-吡啶基)-l-氮杂双环[2.2.2]辛烷(RJR-2429);尼古丁拮抗剂,如甲基牛扁亭碱(Methyllycacotinine)和美卡拉明(Mecamylamine);乙酰胆碱酯酶抑制剂,如加兰他敏(Galantamine)、吡斯的明(Pyridostigmine)、毒扁豆碱(Physostigmine)和他克林(Tacrine);和MAO-抑制剂,如甲氧基-N,N-二甲基色胺、5-甲氧基-α-甲基色胺、α-甲基色胺、异丙氯肼、异丙烟肼、异卡波肼、利奈唑胺(Linezolid),吗氯贝胺(Meclobemide)、N,N-二甲基色胺、苯乙肼、苯乙胺、托洛沙酮(Toloxatone)、反苯环丙胺和色胺。
优选的是,药剂源包括尼古丁源。尼古丁源可包括尼古丁、尼古丁碱、尼古丁盐(如尼古丁盐酸盐、尼古丁酒石酸氢盐或尼古丁二酒石酸盐)或尼古丁衍生物中的一种或多种。
尼古丁源可包括天然尼古丁或合成尼古丁。
尼古丁源可包括纯尼古丁、尼古丁在水性或非水性溶剂中的溶液或液体烟草提取物。
尼古丁源可进一步包括电解质形成化合物。电解质形成化合物可选自由碱金属氢氧化物、碱金属氧化物、碱金属盐、碱土金属氧化物、碱土金属氢氧化物和其组合组成的群组。
尼古丁源可包括选自由以下组成的群组的电解质形成化合物:氢氧化钾、氢氧化钠、氧化锂、氧化钡、氯化钾、氯化钠、碳酸钠、柠檬酸钠、硫酸铵和其组合。
尼古丁源可包括尼古丁、尼古丁碱、尼古丁盐或尼古丁衍生物和电解质形成化合物的水性溶液。
替代地或另外,尼古丁源可进一步包括其它组分,包含但不限于天然香料、人工香料和抗氧化剂。
药剂源可包括如上所述的吸附元件和被吸附在吸附元件上的药剂。在制造期间药剂可被吸附在吸附元件上并且可对吸附元件加以密封。药剂可与吸附元件分开储存,例如储存在吸附元件上或邻近吸附元件的泡壳中。当药剂被释放并且吸附在吸附元件上时,药剂源形成。
气溶胶生成装置优选被配置成加热气溶胶生成制品的药剂源和挥发性递送增强化合物源以使得气溶胶生成制品的药剂源具有比气溶胶生成制品的挥发性递送增强化合物源高的温度。气溶胶生成装置被配置成基本上同时加热气溶胶生成制品的药剂源和挥发性递送增强化合物源。
在上述实施例中的任一个中,气溶胶生成装置和气溶胶生成制品可被配置成将药剂源加热到第一温度,并且将挥发性递送增强化合物源加热到第二温度,其中第一温度高于第二温度至少约50摄氏度、优选高于第二温度至少约70摄氏度、最优选高于第二温度至少约80摄氏度。另外或替代地,第一温度优选不超过高于第二温度约100摄氏度。优选的是,第一和第二温度之间的温差在约50与约100摄氏度之间、更优选在约60与约100摄氏度之间、最优选在约80与约100摄氏度之间。
在上述实施例中的任一个中,气溶胶生成装置和气溶胶生成制品可被配置成将挥发性递送增强化合物源加热到至少约30摄氏度的温度。另外或替代地,气溶胶生成装置和气溶胶生成制品可被配置成将挥发性递送增强化合物源加热到低于约100摄氏度,优选低于约70摄氏度的温度。优选的是,气溶胶生成装置和气溶胶生成制品被配置成将挥发性递送增强化合物源加热到约30与约100摄氏度之间,更优选约30与约70摄氏度之间的温度。
在上述实施例中的任一个中,气溶胶生成装置和气溶胶生成制品可被配置成将药剂源加热到至少约50摄氏度的温度。另外或替代地,气溶胶生成装置和气溶胶生成制品可被配置成将药剂源加热到低于约150摄氏度,优选低于约100摄氏度的温度。优选的是,气溶胶生成装置和气溶胶生成制品被配置成将药剂源加热到约50与约150摄氏度之间,更优选约50与约100摄氏度之间的温度。
气溶胶生成装置可进一步包括被配置成控制对加热器元件的动力供给的控制器。
气溶胶生成装置可进一步包括用于向加热器元件供电的电源和被配置成控制从电源到加热器元件的电力供给的控制器。气溶胶生成装置的控制器可被配置成控制从外部电源到加热器元件的电力供给。
加热器元件可以是由电源供电的电加热器元件。在加热器元件为电加热器元件的情况下,气溶胶生成装置可进一步包括电源和控制器,所述控制器包括电子电路,所述电子电路被配置成控制从电源到电加热器元件的电力供给。
电源可为DC电压源。优选的是,电源为电池。电源可以是镍金属氢化物电池、镍镉电池或锂基电池,例如锂钴、磷酸锂铁或锂聚合物电池。电源可替代地为另一种形式的电荷储存装置,如电容器。电源可能需要再充电并且可具有允许足够的能源储存的容量,以用于气溶胶生成装置与一种或多种气溶胶生成制品。
加热器元件可以是非电加热器,如化学加热构件。
气溶胶生成装置的加热器元件优选包括单一加热器元件以简化气溶胶生成装置的构造。差温加热药剂源和挥发性递送增强化合物源可通过使所述源中的至少一种与弹性构件接触来实现,所述弹性构件反过来偏置抵靠加热器元件。
加热器元件可具有任何合适的形状。优选的是,加热器元件为细长加热器元件。优选的是,细长加热器元件的宽度大于所述加热器元件的厚度以使得加热器元件形成加热器叶片。
优选的是,加热器元件被电加热。然而,可使用其它加热方案来加热加热器元件。加热器元件可通过来自另一热源的传导加热。加热器元件可包括红外加热器元件、光子源或感应加热器元件。
加热器元件可包括散热器或贮热器,其包括能够吸收及储存热量并且随后随时间推移将热量释放到气溶胶形成制品的材料。散热片可由任何合适的材料(如合适的金属或陶瓷材料)形成。优选的是,所述材料具有高热容量(显热储存材料),或是能够经由可逆过程,如高温相变来吸收并且随后释放热的材料。合适的显热储存材料包含硅胶、氧化铝、碳、玻璃垫、玻璃纤维、矿物质、金属或合金(如铝、银或铅)和纤维素材料(如纸)。经由可逆相变释放热的其它合适材料包含石蜡、乙酸钠、萘、蜡、聚环氧乙烷、金属、金属盐、共晶盐的混合物或合金。
优选的是,加热器元件优选包括电阻材料。加热器元件可包括非弹性材料,例如陶瓷烧结材料,如氧化铝(Al2O3)和氮化硅(Si3N4);或印刷电路板或硅橡胶。替代地,加热器元件可包括弹性金属材料,例如铁合金或镍铬合金。
其它合适的电阻材料包含但不限于:半导体,如掺杂陶瓷,电“传导”陶瓷(如二硅化钼)、碳、石墨、金属、金属合金以及由陶瓷材料和金属材料制成的复合材料。此类复合材料可包括掺杂或无掺杂的陶瓷。合适的掺杂陶瓷的实例包含掺杂碳化硅。合适的金属的实例包含钛、锆、钽和铂族金属。合适的金属合金的例子包含不锈钢、镍、钴、铬、铝-钛-锆、铪、铌、钼、钽、钨、锡、镓和锰合金,和基于镍、铁、钴、不锈钢、的超合金以及基于铁-锰-铝的合金。是科罗拉多州丹佛市1999百老汇套房4300的钛金属公司(Titanium Metals Corporation,1999Broadway Suite 4300,Denver,Colorado)的注册商标。在复合材料中,电阻材料可以任选地嵌入绝缘材料中,由绝缘材料封装或由绝缘材料涂布或反之亦然,这取决于能量转移的动力学和所需外部物理化学特性。
气溶胶生成装置可包括一个或多个温度传感器,其被配置成感测加热器元件、药剂源和挥发性递送增强化合物源中的至少一个的温度。在所述实施例中,控制器可被配置成根据感测的温度控制对加热器元件的电力供给。
加热器元件可使用在温度与电阻率之间具有限定关系的金属来形成。在这类实施例中,金属可形成为两层合适的绝缘材料之间的迹线。以这种方式形成的加热器元件可用作加热器和温度传感器。
附图说明
本发明现将参照附图,仅通过举例来进一步描述,其中:
图1显示包括根据本发明的第一实施例的气溶胶生成制品的气溶胶生成系统;
图2显示沿线1-1获取的图1的气溶胶生成系统的横截面,其中可移动部分处于关闭位置;
图3显示沿线1-1获取的图1的气溶胶生成系统的横截面,其中可移动部分处于打开位置;
图4显示包括根据本发明的第二实施例的气溶胶生成制品的气溶胶生成系统,其中可移动部分处于关闭位置;并且
图5显示图4的气溶胶生成系统,其中可移动部分处于打开位置。
具体实施方式
相同参考编号将用于表示以下附图描述中的相同部件。
图1显示包括根据本发明的一个实施例的气溶胶生成制品12以及气溶胶生成装置14的气溶胶生成系统10。气溶胶生成装置14包括呈加热器叶片形式的加热器元件16。加热器元件16被电加热并且气溶胶生成装置可包括电源和控制电子元件,如本领域中已知。
气溶胶生成制品12包括上游主体部分17,所述上游主体部分17包括上游部分18和下游部分20,所述上游部分18与气溶胶生成装置14连接,在所述下游部分20上提供药剂源22和挥发性递送增强化合物源24。药剂源22和挥发性递送增强化合物源24中的每一个提供在下游部分20的表面处的凹部26中。
气溶胶生成装置14的加热器叶片16被容纳在上游主体部分17的下游部分20的腔28中。导热板30提供在腔28中的下游部分20的表面上并且邻近药剂源22。加热器元件16接触导热板30以使得在操作装置期间热量被转移到药剂源22。导热板30并未延伸到挥发性递送增强化合物源24的下方,以使得挥发性递送增强化合物源24被加热到比药剂源22低的温度。
气溶胶生成制品12进一步包括下游主体部分32和从下游主体部分32的下游端延伸的烟嘴34。上游主体部分17上的圆形凸缘36位于下游主体部分32中的环形槽38中以使得下游主体部分32可围绕圆形凸缘36旋转。气流入口37限定在上游主体部分17和下游主体部分32之间,并且烟嘴34提供气流出口。气流通道39在气流入口37和烟嘴34之间延伸。
如显示图1中沿线1-1获取的气溶胶生成制品12的横截面图的图2和3中较清楚显示,第一和第二箔密封件40和42各自包括固定到下游主体部分32的第一端部和固定到上游主体部分17的下游部分20的第二端部。当如图2所示,下游主体部分32处于关闭位置时,第一和第二箔密封件40和42覆盖凹部26,在所述凹部26中提供有药剂源22和挥发性递送增强化合物源24。沿圆周方向44将下游主体部分32旋转到打开位置处,如图3中所示,会使箔密封件40和42从凹部26剥离而暴露药剂源22和挥发性递送增强化合物源24。下游主体部分32可在打开位置与关闭位置之间移动以反复地解封和密封凹部26。
图4和5显示一种气溶胶生成系统100,其包括根据本发明的第二实施例的气溶胶生成制品102和气溶胶生成装置14,如根据先前实施例所述。
气溶胶生成制品102包括管状外部壳体104,其中安装有上游环形止动器106和下游环形止动器108。在环形止动器106和108之间延伸的是第一破裂构件110和第二破裂构件112,其各自包括具有上游突起部114和下游突起部116的细长板。第一破裂构件110上的突起部114和116各自包括一个或多个气流孔118以允许气流进入限定在第一和第二破裂构件110和112之间的空间中的气流通道。外部壳体104中的气流入口119允许空气流入气溶胶生成制品102中。
经成形用于插入凹部中形成第一破裂构件110上的下游突起部116的按钮120延伸通过外部壳体104中的开孔。按钮120允许用户选择性地打开和关闭第一破裂构件110的上游突起部中的气流开孔118以在活化气溶胶生成制品102之后防止或允许空气流通过气溶胶生成制品102。按钮120显示在图4中的关闭位置处和图5中的打开位置处。
气溶胶生成制品102进一步包括以可滑动方式容纳在外部壳体104的下游端中的管状段122。如先前所述,烟嘴34从管状段122向下游延伸。弹性构件124从管状段122向上游延伸并且位于第一破裂构件110和第二破裂构件112之间。弹性构件124弹性地偏置抵靠气溶胶生成装置14的加热器元件16。弹性构件124由能够承受加热器元件16的操作温度的导热弹性材料(如金属)形成。
药剂泡壳126提供在弹性构件124上,药剂泡壳126包括含有液体药剂,如尼古丁的泡壳。泡壳形成含有液体药剂的易破阻挡层。类似地,挥发性递送增强化合物泡壳128提供在弹性构件124上,挥发性递送增强化合物泡壳128包括含有液体挥发性递送增强化合物,如丙酮酸的泡壳。泡壳形成含有液体挥发性递送增强化合物的易破阻挡层。第一及第二吸附元件130和132提供在弹性构件124上而分别邻近药剂泡壳126和挥发性递送增强化合物泡壳128。
为了活化气溶胶生成制品102,用户将管状段122滑动到外部壳体104中直到所述管状段抵靠下游环形止动器108为止。将管状段122滑动到外部壳体104中还会将弹性构件124进一步滑动到外部壳体104中,以使得药剂泡壳126和挥发性递送增强化合物泡壳128在第一和第二破裂构件110和112的上游和下游突起部114和116之间被挤压和破裂,如图5所示。泡壳破裂引起药剂和挥发性递送增强化合物源中的至少一些被分别吸附在第一和第二吸附130和132上。具有吸收在其上的药剂中的至少一些的第一吸附元件130形成接触弹性构件124的药剂源22。类似地,具有吸收在其上的挥发性递送增强化合物中的至少一些的第二吸附元件132形成接触在药剂源22下游的弹性构件124的挥发性递送增强化合物源24。
在操作气溶胶生成系统100期间,加热器元件16通过弹性构件124加热药剂源22和挥发性递送增强化合物源24。药剂源22位于在挥发性递送增强化合物源24上游的弹性构件124上并且因此更接近于加热器元件16。因此,加热器元件16将药剂源22加热到比挥发性递送增强化合物源24高的温度。
Claims (12)
1.一种气溶胶形成制品,其包括:
气流入口和气流出口;
药剂源和挥发性递送增强化合物源,二者位于所述气流入口与所述气流出口之间;以及
可移动部分,其能够在打开位置与关闭位置之间移动,在所述打开位置处,所述药剂源和所述挥发性递送增强化合物源与所述气流入口和所述气流出口两者流体连通,在所述关闭位置处,所述药剂源和所述挥发性递送增强化合物源中的每一个与所述气流入口和所述气流出口均不连通或仅与所述气流入口和所述气流出口中的一个连通。
2.根据权利要求1所述的气溶胶形成制品,其进一步包括内部部分,所述药剂源和所述挥发性递送增强化合物源设置于所述内部部分上,并且其中所述可移动部分包括包含所述内部部分的外部壳体,所述外部壳体被配置成能够相对于所述内部部分移动。
3.根据权利要求2所述的气溶胶形成制品,其进一步包括至少一个密封件,所述至少一个密封件包括固定到所述外部壳体的内表面的第一端部和固定到所述内部部分的第二端部,其中所述外部壳体的内表面与所述内部部分间隔开,并且其中所述外部壳体能够在所述关闭位置与所述打开位置之间移动,在所述关闭位置处,所述至少一个密封件覆盖所述药剂源和所述挥发性递送增强化合物源,在所述打开位置处,所述药剂源和所述挥发性递送增强化合物源至少部分未被覆盖。
4.根据权利要求2所述的气溶胶形成制品,其中所述外部壳体能够在所述关闭位置与所述打开位置之间移动,在所述关闭位置处,所述外部壳体的内表面接触所述内部部分并且覆盖所述药剂源和所述挥发性递送增强化合物源,在所述打开位置处,所述外部壳体的内表面与所述内部部分间隔开以使得所述药剂源和所述挥发性递送增强化合物源未被覆盖。
5.根据权利要求4所述的气溶胶形成制品,其中所述外部壳体的内表面包括锥形部分。
6.根据权利要求1所述的气溶胶形成制品,其进一步包括:
外部壳体,所述气流入口和所述气流出口设置于所述外部壳体上;
气流通道,其包含于所述外部壳体中并且在所述气流入口与所述气流出口之间延伸,其中所述药剂源和所述挥发性递送增强化合物源设置在所述气流通道中;以及
其中所述可移动部分能够在所述关闭位置与所述打开位置之间移动,在所述关闭位置处,所述可移动部分阻碍所述气流通道以防止在所述气流入口与所述气流出口之间的、通过所述气流通道的气体流动,在所述打开位置处,所述气流通道不受阻碍。
7.根据权利要求6所述的气溶胶形成制品,其中所述可移动部分包括第一端部和第二端部,所述第一端部被配置成当所述可移动部分处于所述关闭位置时阻碍所述气流通道,所述第二端部延伸通过所述外部壳体中的开孔,以允许用户借助所述可移动部分的第二端部在所述打开位置与所述关闭位置之间移动所述可移动部分。
8.根据任一前述权利要求所述的气溶胶生成制品,其中所述药剂源包括尼古丁源。
9.根据任一前述权利要求所述的气溶胶生成制品,其中所述挥发性递送增强化合物源包括酸。
10.一种气溶胶生成系统,其包括气溶胶生成装置以及根据任一前述权利要求所述的气溶胶形成制品,所述气溶胶生成装置包括加热器元件。
11.根据权利要求10所述的气溶胶生成系统,其中所述气溶胶生成装置和所述气溶胶形成制品被配置成将所述药剂源加热到50与150摄氏度之间的温度。
12.根据权利要求10或11所述的气溶胶生成系统,其中所述气溶胶生成装置和所述气溶胶形成制品被配置成将所述挥发性递送增强化合物源加热到30与100摄氏度之间的温度。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP15161536 | 2015-03-27 | ||
EP15161536.6 | 2015-03-27 | ||
CN201680015125.9A CN107427077B (zh) | 2015-03-27 | 2016-03-24 | 可重复密封的气溶胶生成制品 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201680015125.9A Division CN107427077B (zh) | 2015-03-27 | 2016-03-24 | 可重复密封的气溶胶生成制品 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN112656038A true CN112656038A (zh) | 2021-04-16 |
Family
ID=52875493
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110052335.8A Pending CN112656038A (zh) | 2015-03-27 | 2016-03-24 | 可重复密封的气溶胶生成制品 |
CN201680015125.9A Active CN107427077B (zh) | 2015-03-27 | 2016-03-24 | 可重复密封的气溶胶生成制品 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201680015125.9A Active CN107427077B (zh) | 2015-03-27 | 2016-03-24 | 可重复密封的气溶胶生成制品 |
Country Status (10)
Country | Link |
---|---|
US (1) | US10786007B2 (zh) |
EP (1) | EP3273813B1 (zh) |
JP (1) | JP6925276B2 (zh) |
KR (1) | KR102601370B1 (zh) |
CN (2) | CN112656038A (zh) |
CA (1) | CA2978384A1 (zh) |
IL (1) | IL253329A0 (zh) |
MX (1) | MX2017012360A (zh) |
RU (1) | RU2692827C2 (zh) |
WO (1) | WO2016156216A1 (zh) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201800500D0 (en) | 2018-01-11 | 2018-02-28 | Project Paradise Ltd | A mouthpiece assmebly for an inhalation device including a replaceable substrate component,and a replaceable substrate component therefor |
ES2930090T3 (es) | 2018-06-21 | 2022-12-07 | Philip Morris Products Sa | Unidad de cartucho activable y resellable para un sistema generador de aerosol |
JP7295149B2 (ja) * | 2018-06-29 | 2023-06-20 | フィリップ・モーリス・プロダクツ・ソシエテ・アノニム | エアロゾル送達が強化されたエアロゾル発生システム |
CA3107413A1 (en) * | 2018-07-23 | 2020-01-30 | Juul Labs, Inc. | Airflow management for vaporizer device |
US20200035118A1 (en) | 2018-07-27 | 2020-01-30 | Joseph Pandolfino | Methods and products to facilitate smokers switching to a tobacco heating product or e-cigarettes |
US10897925B2 (en) | 2018-07-27 | 2021-01-26 | Joseph Pandolfino | Articles and formulations for smoking products and vaporizers |
GB201816831D0 (en) * | 2018-10-16 | 2018-11-28 | Nicoventures Trading Ltd | Aerosol provision device |
US20200221785A1 (en) * | 2019-01-10 | 2020-07-16 | Altria Client Services Llc | Vaping device with insert |
WO2020148334A1 (en) * | 2019-01-15 | 2020-07-23 | Philip Morris Products S.A. | Aerosol-generating device with movable top cover |
GB201901067D0 (en) * | 2019-01-25 | 2019-03-13 | Nicoventures Trading Ltd | Assembly for insertion into an aerosol provision device |
CN113766843A (zh) * | 2019-05-03 | 2021-12-07 | 日本烟草国际股份有限公司 | 具有关闭件的气溶胶产生装置 |
TWI789584B (zh) * | 2019-05-03 | 2023-01-11 | 瑞士商傑太日煙國際股份有限公司(瑞士) | 具有關閉件之氣溶膠產生裝置及用於操作氣溶膠產生裝置之方法 |
AU2021318431C1 (en) | 2020-07-29 | 2023-11-30 | Monster Color Carnival Llc | Delivery system for ayahuasca-like substances |
KR102357563B1 (ko) | 2020-12-14 | 2022-02-07 | 인탑스 주식회사 | 전자회로 도금 공법을 이용한 ime 구조 및 그 제조방법 |
KR102394587B1 (ko) | 2021-07-19 | 2022-05-06 | 인탑스 주식회사 | 다중 ime 구조 및 그 제조 방법 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1889861A (zh) * | 2003-12-05 | 2007-01-03 | Lts罗曼治疗方法有限公司 | 碱性药物吸入器及其制造方法 |
CN103237469A (zh) * | 2010-12-03 | 2013-08-07 | 菲利普莫里斯生产公司 | 防止冷凝物泄漏的气雾剂生成系统 |
CN104080359A (zh) * | 2012-02-13 | 2014-10-01 | 菲利普莫里斯生产公司 | 空气流动改进的发烟制品 |
WO2015000974A1 (en) * | 2013-07-03 | 2015-01-08 | Philip Morris Products S.A. | Multiple use aerosol-generating system |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1880007A2 (en) | 2005-05-05 | 2008-01-23 | Genencor International, Inc. | Personal care compositions and methods for their use |
CN201067079Y (zh) | 2006-05-16 | 2008-06-04 | 韩力 | 仿真气溶胶吸入器 |
EP2113178A1 (en) | 2008-04-30 | 2009-11-04 | Philip Morris Products S.A. | An electrically heated smoking system having a liquid storage portion |
MX2012003315A (es) | 2009-09-16 | 2012-06-08 | Philip Morris Products Sa | Dispositivo y metodo mejorados para el suministro de un medicamento. |
CN102894486A (zh) * | 2012-11-07 | 2013-01-30 | 修运强 | 螺旋驱动的滑动刺入式电子烟具 |
CN104994757B (zh) | 2013-03-15 | 2018-05-18 | 菲利普莫里斯生产公司 | 利用差温加热的气雾生成系统 |
SG11201508686UA (en) | 2013-05-21 | 2015-11-27 | Philip Morris Products Sa | Electrically heated aerosol delivery system |
US10194693B2 (en) | 2013-09-20 | 2019-02-05 | Fontem Holdings 1 B.V. | Aerosol generating device |
KR102400324B1 (ko) | 2013-12-05 | 2022-05-20 | 필립모리스 프로덕츠 에스.에이. | 비-담배 니코틴-함유 물품 |
-
2016
- 2016-03-24 RU RU2017134788A patent/RU2692827C2/ru active
- 2016-03-24 CA CA2978384A patent/CA2978384A1/en not_active Abandoned
- 2016-03-24 CN CN202110052335.8A patent/CN112656038A/zh active Pending
- 2016-03-24 US US15/555,737 patent/US10786007B2/en active Active
- 2016-03-24 CN CN201680015125.9A patent/CN107427077B/zh active Active
- 2016-03-24 KR KR1020177024612A patent/KR102601370B1/ko active IP Right Grant
- 2016-03-24 MX MX2017012360A patent/MX2017012360A/es unknown
- 2016-03-24 JP JP2017547952A patent/JP6925276B2/ja active Active
- 2016-03-24 WO PCT/EP2016/056578 patent/WO2016156216A1/en active Application Filing
- 2016-03-24 EP EP16711666.4A patent/EP3273813B1/en active Active
-
2017
- 2017-07-05 IL IL253329A patent/IL253329A0/en unknown
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1889861A (zh) * | 2003-12-05 | 2007-01-03 | Lts罗曼治疗方法有限公司 | 碱性药物吸入器及其制造方法 |
CN103237469A (zh) * | 2010-12-03 | 2013-08-07 | 菲利普莫里斯生产公司 | 防止冷凝物泄漏的气雾剂生成系统 |
CN104080359A (zh) * | 2012-02-13 | 2014-10-01 | 菲利普莫里斯生产公司 | 空气流动改进的发烟制品 |
WO2015000974A1 (en) * | 2013-07-03 | 2015-01-08 | Philip Morris Products S.A. | Multiple use aerosol-generating system |
Also Published As
Publication number | Publication date |
---|---|
US10786007B2 (en) | 2020-09-29 |
EP3273813A1 (en) | 2018-01-31 |
IL253329A0 (en) | 2017-09-28 |
CN107427077B (zh) | 2021-02-02 |
RU2017134788A (ru) | 2019-04-04 |
WO2016156216A1 (en) | 2016-10-06 |
MX2017012360A (es) | 2017-12-18 |
US20180042305A1 (en) | 2018-02-15 |
RU2692827C2 (ru) | 2019-06-28 |
KR102601370B1 (ko) | 2023-11-13 |
JP6925276B2 (ja) | 2021-08-25 |
RU2017134788A3 (zh) | 2019-04-23 |
CN107427077A (zh) | 2017-12-01 |
JP2018510629A (ja) | 2018-04-19 |
KR20170130395A (ko) | 2017-11-28 |
EP3273813B1 (en) | 2022-10-05 |
CA2978384A1 (en) | 2016-10-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN107427077B (zh) | 可重复密封的气溶胶生成制品 | |
US20210219614A1 (en) | Aerosol-generating system comprising integrated piercing element | |
US10806873B2 (en) | Aerosol-generating system comprising a resilient member | |
KR102581030B1 (ko) | 바이메탈 스트립을 포함하는 에어로졸 발생 시스템 | |
US11805809B2 (en) | Aerosol-generating system comprising a rupturing portion |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |